



NEWS RELEASE

# Evolus to Participate in the H.C. Wainwright Global Investment Conference

5/11/2022

NEWPORT BEACH, Calif.--(BUSINESS WIRE)-- Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products, today announced that members of its management team will be participating in the H.C. Wainwright Global Investment Conference.

---

Event: H.C. Wainwright Global Investment Conference  
Date: Tuesday, May 24, 2022  
Time: 9:00-9:30 am ET

An audio webcast of this event will be available on the investor relations section of Evolus' website at [www.evolus.com](http://www.evolus.com). A replay of the webcast will be available for 90 days after the date of the presentation.

## About Evolus, Inc.

Evolus (Nasdaq: EOLS) is a performance beauty company with a customer-centric approach to delivering breakthrough products. Approved in 2019 by the U.S. Food and Drug Administration, Jeuveau® (prabotulinumtoxinA-xvfs) is the first and only neurotoxin dedicated exclusively to aesthetics and manufactured in a state-of-the-art facility using Hi-Pure™ technology. Jeuveau® is powered by Evolus' unique technology platform and is designed to transform the aesthetic market by eliminating the friction points existing for customers today. Visit us at [www.evolus.com](http://www.evolus.com) and follow us on [LinkedIn](#), [Twitter](#), [Instagram](#) or [Facebook](#).

Jeuveau® is a registered trademark of Evolus, Inc.



Hi-Pure™ is a trademark of Daewoong Pharmaceutical Co, Ltd.

Investor/Media Contact:

David K. Erickson, Evolus, Inc.

Vice President, Investor Relations

Tel: 949-966-1798

Email: **david.erickson@evolus.com**

Source: Evolus